Fig. 2: Best response to RVD and ASCT. | Blood Cancer Journal

Fig. 2: Best response to RVD and ASCT.

From: Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Fig. 2

Percentage of patients achieving at least a complete response (≥CR), very good partial response (≥VGPR), and partial response (≥PR) to RVD induction and ASCT is demonstrated. Patients were grouped by presence or absence of +1q and best response after completion of induction or transplant.

Back to article page